Genotoxicity of doxorubicin in F344 rats by combining the comet assay, flow-cytometric peripheral blood micronucleus test, and pathway-focused gene expression profiling

Environmental and Molecular Mutagenesis

Volumn 55, Issue 1, 2014, Pages 24-34

  Manjanatha, Mugimane G ^a   Bishop, Michelle E ^a   Pearce, Mason G ^a   Kulkarni, Rohan ^b   Lyn Cook, Lascelles E ^a   Ding, Wei ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b BioReliance Corporation   (United States)

Author keywords

Comet assay; Doxorubicin; Gene expression; Micronucleus assay

Indexed keywords

DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; CARDIOTOXICITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; FISCHER 344 RAT; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENOTOXICITY; HISTOPATHOLOGY; IN VIVO STUDY; MICRONUCLEUS TEST; NONHUMAN; PATHOGENESIS; RAT; RETICULOCYTE;

RATTUS;

EID: 84890862210     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21822     Document Type: Article

References (50)

1. Angelis K J, Dusinska M, Collins AR. 1999. Single cell gel electrophoresis: detection of DNA damage at different levels of sensitivity. Electrophoresis 20:2133-2138.
2. Azqueta A, Shaposhnikov S, Collins AR. 2009. DNA oxidation: Investigating its key role in environmental mutagenesis with the comet assay. Mutat Res 674:101-108.
3. Baumgartner A, Schmid TE, Cemeli E, Anderson D. 2004. Parallel evaluation of doxorubicin-induced genetic damage in human lymphocytes and sperm using the comet assay and spectral karyotyping. Mutagenesis 19:313-318.
4. Berthiaume JM, Wallace KB. 2007. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23:15-25.
5. Burke JR, Lauciu JF, Brodvsky HS, Spriano RZ. 1977. Doxorubicin hydrochloride-associated renal failure. Arch Intern Med 137:385-389.
6. Calandra T, Roger T. 2003. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3:791-800.
7. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. 2007. Molecualar and cellular mechanisms of anthracyclin cardiotoxicity. Cardiovasc Toxicol 7:114-121.
8. Collins AR. 2004. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26:249-261.
9. Cullinane C, Phillips DR. 1990. Induction of stable transcriptional blockage sites by Adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron (III) ions. Biochemistry 29:5638-5646.
10. Cullinane C, Cutts SM, Van Rosmalen A, Phillips DR. 1994. Formation of adriamycin-DNA adducts in vitro. Nucleic Acids Res 22:2296-2303.
11. Dardir M, Herman EH, Ferrans VJ. 1989. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 23:269-275.
12. Deepa PR, Varalakshmi P. 2006. Influence of low-molecular weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity. Toxicology 217:176-183.
13. Ding W, Levy DD, Bishop ME, Lyn-Cook LE, Kulkarni R, Chang CW, Aidoo A, Manjanatha MG. 2011. Methyleugenol genotoxicity in the Fischer 344 rat using the comet assay and pathway-focused gene expression profiling. Toxicol Sci 123:103-112.
14. Doroshow JH, Locker GY, Myers CE.1980. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 65:128-135.
15. Dusinska M. 2000. THE COMET ASSAY, modified for detection of oxidized bases with the use of bacterial repair endonucleases. http://www.cometassayindia.org/Dusinska-protocol.PDF.
16. Gatta G, Capocaccia R, Coleman MP, Ries LA, Bernini F. 2002. Childhood cancer survival in Europe and the United States. Cancer 95:1767-1772.
17. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
18. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. 2008. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784.
19. Haq MM, Legha SS, Choski J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M. 1985. Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361-1365.
20. Hashimoto K, Takasaki W, Sato I, Tsuda S. 2007. DNA damage measured by comet assay and 8-OH-dG formation related to blood chemical analyses in aged rats. J Toxicol Sci 32:249-259.
21. Herman EH, Ferrans VJ. 1998. Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity. Prog Pediatr Cardiol 8:49-58.
22. Herman EH, El-Hage A, Ferrans VJ. 1988. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92:42-53.
23. JaCVAM. 2009. International validation of the in vivo alakaline comet assay for the detection of genotoxic carcinogens. Version 14.2. http://Cometassay.com/JaCVAM.PDF.
24. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. 2006. Cancer statistics. CA Cancer J Clin 56:106-130.
25. Johnson BA, Cheang MS, Goldenberg GJ. 1986. Comparison of adriamycin uptake n chick embryo heart and liver cells of murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity. Cancer Res 46:218-223.
26. Krischer JP, Epstein S, Cuthberston DD, Goorin AM, Epstein ML, Lipshultz SE. 1997. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric Oncology Group Experience. J Clin Oncol 15:1544-1552.
27. Lahdetie J. 1983. Meiotic micronuclei induced by adriamycin in male rats. Mutat Res 119:79-82.
28. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, Heide RV. 2006. DNA damage is an early event in doxorubicin-inducedcardiac myocyte death. Am J Physiol Heart Cir Physiol 291:H1273-H1280.
29. Lipshultz SE, Cohen H, Colan SD. 2006. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity. Leuk Lymphoma 47:1454-1458.
30. Livak KJ, and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
31. Manjanatha MG, Aidoo A, Shelton SD, Bishop ME, McDaniel LP, Lyn-Cook LE, Doerge DR. 2006. Genotoxicity of acrylamide and its metabolite glycidamide administered in drinking water to male and female Big Blue mice. Environ Mol Mutagen 47:6-17.
32. Martins RA, Minari AL, Chaves MD, Santos RWT, Barbisan LF, Ribeiro DA. 2012. Exercise preconditioning modulates genotoxicity induced by doxorubicin in multiple organs of rats. Cell Biochem Funct 30:293-296.
33. Menna P, Salvatorelli E, Minotti G. 2008. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
34. Mettler FP, Young DM, Ward JM. 1977. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37:2705-2713.
35. Myers C. 1998. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25:10-14.
36. Oshida K, Iwanaga E, Miyamoto-Kuramitsu K, Miyamoto Y. 2008. An in vivo comet assay of multiple organs (liver, kidney and bone marrow) in mice treated with methyl methanesulfonate and acetaminophen accompanied by hematology and/or blood chemistry. J Toxicol Sci 33:515-524.
37. Phillips Dr, White RJ, Cullinane C. 1989. DNA sequence specific adducts of adriamycin and mitomycin C. FEBS Lett 246:233-240.
38. Sasaki YF, Saga A, Akasaka M, Nishidate E, Watanabe-Akanuma M, Ohta T, Matsusaka N, Tsuda S. 1997. In vivo genotoxicity of heterocyclic amines detected by a modified alkaline single cell gel electrophoresis assay in a multiple organ study in the mouse. Mutat Res 395:57-73.
39. Sasaki YF, Sekihashi K, Izumiyama F, Nishidate E, Saga A, Ishida K, Tsuda S. 2000. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and U.S. NTP Carcinogenicity Database. Crit Rev Toxicol 30:629-799.
40. Simunek T, Striba M, Popelova O, Adamcova M, Hrdina R, Gers V. 2009. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171.
41. Singal PK, Deally CM, Weinberg LE. 1987. Subcellular effects of adriamycin in the heart: A concize review. J Mol Cell Cardiol 19:817-828.
42. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
43. Smith CC, O'Donovan MR, Martin EA. 2006. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 21:185-190.
44. Takemura G, Fujiwara H. 2007. Doxorubicin induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352.
45. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
46. Todorova AK, Kaufmann Y, Hennings L, Klimberg VS. 2010. Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr 140:44-48.
47. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Walliman T, Schlattner U. 2006. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405.
48. Tsai CA, Chen JJ. 2009. Multivariate analysis of variance test for gene set analysis. Bioinformatics 25:897-903.
49. Zhang J, Clark JR, Herman EH, Ferrans VJ. 1996. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney, and intestine and inhibition by ICRF-187. J Mol Cell Cardiol 28:1931-1943.
50. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. 2001. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61:771-777.